[{"id":"46c08f17-26c5-4730-b84c-c4364ca8da5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02545361","created_at":"2021-01-19T08:29:28.970Z","updated_at":"2024-07-02T16:37:07.837Z","phase":"Phase 1/2","brief_title":"Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients","source_id_and_acronym":"NCT02545361","lead_sponsor":"Kahr Medical","biomarkers":" FAS • CD80 • CD86","pipe":"","alterations":" ","tags":["FAS • CD80 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KAHR-102 • dexamethasone injection"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2018","start_date":" 04/01/2018","primary_txt":" Primary completion: 04/01/2020","primary_completion_date":" 04/01/2020","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2018-08-16"}]